Comparing Jaguar Animal Health (JAGX) and Its Peers
Jaguar Animal Health (NASDAQ: JAGX) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Jaguar Animal Health to similar companies based on the strength of its institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.
This table compares Jaguar Animal Health and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jaguar Animal Health||-757.17%||N/A||-301.91%|
|Jaguar Animal Health Competitors||-3,989.53%||-119.68%||-44.40%|
This is a breakdown of recent ratings for Jaguar Animal Health and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jaguar Animal Health||0||0||2||0||3.00|
|Jaguar Animal Health Competitors||469||2235||6130||118||2.66|
Jaguar Animal Health presently has a consensus target price of $2.00, indicating a potential upside of 920.41%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.05%. Given Jaguar Animal Health’s stronger consensus rating and higher possible upside, research analysts clearly believe Jaguar Animal Health is more favorable than its peers.
Volatility & Risk
Jaguar Animal Health has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Jaguar Animal Health’s peers have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Insider and Institutional Ownership
7.1% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 19.5% of Jaguar Animal Health shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Jaguar Animal Health and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Jaguar Animal Health||$1.79 million||N/A||-0.19|
|Jaguar Animal Health Competitors||$207.83 million||-$2.34 million||0.17|
Jaguar Animal Health’s peers have higher revenue, but lower earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Jaguar Animal Health beats its peers on 6 of the 11 factors compared.
Jaguar Animal Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
Receive News & Ratings for Jaguar Animal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.